Fact based stock research
Chunghwa Chemical Synthesis & Biotech (TSEC:1762)

TW0001762003

How to read the free ranks

For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. The higher the rank, the better the stock performs than its peers. And, we do this for six investment strategies:
Value - shows how good of a value the stock is. Green is "inexpensive"; red is "expensive".

Growth - shows a company's growth potential. Green is "high growth" expected; red is "tough times ahead".

Safety - relates to the amount of debt a company has. Green is low debt level; red is high debt level.

Combined Financial - this isn't an average of the first three ranks but rather a consolidated view across several financial indicators. Green = good; red = tread carefully.

(NEW) Sentiment - quantifies professional analyst ratings and holdings as well as market pulse. Green = positive sentiment; red = skepticism (Only available to Premium Subscribers).

(NEW) 360° View - the ultimate rating with all financial and non-financial indicators.

Chunghwa Chemical Synthesis & Biotech stock research in summary

ccsb.com.tw

ANALYSIS: With an Obermatt Combined Rank of 6 (worse than 94% compared with investment alternatives), Chunghwa Chemical Synthesis & Biotech (Pharmaceuticals, Taiwan) shares have lower financial characteristics compared with similar stocks. Shares of Chunghwa Chemical Synthesis & Biotech are low in value (priced high) with a consolidated Value Rank of 36 (worse than 64% of alternatives), show below-average growth (Growth Rank of 4), and are riskily financed (Safety Rank of 37), which means above-average debt burdens. ...read more

RECOMMENDATION: A Combined Rank of 6, is a sell recommendation based on Chunghwa Chemical Synthesis & Biotech's financial characteristics. As the company Chunghwa Chemical Synthesis & Biotech's key financial metrics all exhibit below-average performance, such as low value (Obermatt Value Rank of 36), low growth (Obermatt Growth Rank of 4), and risky financing practices (Obermatt Safety Rank of 37), it is a somewhat questionable stock investment, where the risk of paying too much for the shares is significant, unless the company has an exceptionally bright future. Such poor financial performance sometimes indicates that the company's business is all concentrated in some distant future. This is sometimes the case for high-tech or biotechnology companies. If they own properties that only provide cash flows in the future, the stock may look excessively expensive and risky today. In such cases, the Obermatt Method has limited value as it is based on facts we can observe today. If the facts are all in the future, stock investing becomes guesswork, and this should only be a driver in a limited number of investments that should only amount to a small fraction of a safe portfolio. Obermatt Premium subscribers can further check the stock’s Sentiment Ranks, which also flow into the Obermatt 360° View for investors. ...read more

Latest Obermatt Ranks


360° View^new
Sentiment Rank^new
Value Rank	36
Growth Rank	4
Safety Rank	37
Combined Rank	6

Country	Taiwan
Industry	Pharmaceuticals
Index	FTSE Taiwan
Size class	X-Small

31-Jul-2025. Stock data may be delayed. Log in or sign up to get the most recent research.

Further information

Multiple opinions. One number.

Analysts rarely agree on a stock’s future. So, who do you believe? Obermatt translates those collective views into a single Sentiment Rank. That plus the financial ranks give you the ultimate 360° View. Sign up to access them.

Why popular stocks have low ratings

It’s easier said than done. When your stock drops, it’s easy to want to sell it and find a better performer. Think twice, or even three times, before trading. Those fees (especially the hidden ones) can eat up your gains.

Review the performance ranks of the individual metrics that form each investment strategy.

Research History: Chunghwa Chemical Synthesis & Biotech

RESEARCH HISTORY	2022	2023	2024	2025
VALUE
VALUE	73	80	54	36
GROWTH
GROWTH	100	47	14	4
SAFETY
SAFETY	72	61	38	37
SENTIMENT
SENTIMENT	100	41	70	^new
360° VIEW
360° VIEW	100	64	38	^new

Most recent update of the stock research: 31-Jul-2025. Financial reporting date used for calculating ranks: 31-Mar-2025. Stock research history is based on the Obermatt Method. The higher the rank, the better Chunghwa Chemical Synthesis & Biotech is in the corresponding investment strategy.
Upgrade to a Premium Account to access the latest ranks.

Combined financial peformance in Detail

RESEARCH HISTORY	2022	2023	2024	2025
VALUE
VALUE	73	80	54	36
GROWTH
GROWTH	100	47	14	4
SAFETY
SAFETY	72	61	38	37
COMBINED
COMBINED	100	79	13	6

Last update of combined financial performance: 31-Jul-2025. Stock analysis on combined financial performance: The higher the rank of Chunghwa Chemical Synthesis & Biotech the better the performance.

Value Metrics in Detail

ANALYSIS: With an Obermatt Value Rank of 36 (worse than 64% compared with alternatives), Chunghwa Chemical Synthesis & Biotech shares are more expensive than the average comparable stock. The Value Rank is based on consolidating four value indicators, where half the indicators are below and half above average for Chunghwa Chemical Synthesis & Biotech. Price-to-Sales (P/S) is 50, which means that the stock price compared with what market professionals expect for future sales is lower than for 50% of comparable companies, indicating a good value concerning Chunghwa Chemical Synthesis & Biotech's revenue size. The same is valid for the Price-to-Book Capital ratio (also referred to as market-to-book ratio), which is more favorable than for 95% of alternatives (5% of peers have a higher ratio). But expected dividend yields with a Dividend Yield rank of 30 are lower than average (dividends are expected to be lower than 70% of other stocks) while the Price to Profit ratio (or Price to Earnings (P/E) ratio) is higher than average with a Price-to-Profit Rank of 8, making the stock more expensive compared with the company's expected profit levels. ...read more

RECOMMENDATION: The overall picture with a consolidated Value Rank of 36, is a hold recommendation based on Chunghwa Chemical Synthesis & Biotech's stock price compared with the company's operational size and dividend yields. Low profits and low dividends as seen here for Chunghwa Chemical Synthesis & Biotech may indicate a restructuring phase. This could be transitory, making the company a good value when profits recover and dividends return to higher levels. If the stock price is compared with the size indicators for revenue and invested capital, it is on the lower side, making this stock a good value investment (apart from current profit and dividend expectations). We recommend further analyzing the stock with Obermatt’s Value, Safety, and Sentiment Ranks, including the 360° View, before making an investment decision. ...read more

VALUE METRICS	2022	2023	2024	2025
PRICE VS. REVENUES (P/S)
PRICE VS. REVENUES (P/S)	63	57	51	50
PRICE VS. PROFITS (P/E)
PRICE VS. PROFITS (P/E)	95	97	26	8
PRICE VS. CAPITAL (Market-to-Book)
PRICE VS. CAPITAL (Market-to-Book)	63	65	83	95
DIVIDEND YIELD
DIVIDEND YIELD	65	67	64	30
CONSOLIDATED RANK: VALUE
CONSOLIDATED RANK: VALUE	73	80	54	36

Last update of Value Rank: 31-Jul-2025. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Chunghwa Chemical Synthesis & Biotech; except for dividend yield where the rank is higher, the higher the yield.

Growth Metrics in Detail

ANALYSIS: With an Obermatt Growth Rank of 4 (better than 4% compared with alternatives), Chunghwa Chemical Synthesis & Biotech shows one of the most restricted growth dynamics in its industry. There is little momentum in this company. The Growth Rank is based on consolidating four value indicators, with all four metrics below average for Chunghwa Chemical Synthesis & Biotech. Sales Growth has a rank of 1, which means that currently professionals expect the company to grow less than 99% of its competitors. The same is valid for Profit Growth, with a rank of 25, and Capital Growth with 42. In addition, Stock Returns have a below market rank of 8, which means that the stock returns have recently been below 92% of alternative investments. ...read more

RECOMMENDATION: The overall picture with a consolidated Growth Rank of 4, is a sell recommendation for growth and momentum investors. These are all bad growth momentum indicators. These are negative signals for investors interested in growth companies. Value is likely good for this company, as investors may have left this stock in the cold. If that is the case, investors should look at the company's outlook, especially Sentiment performance, because it may be a turnaround situation that could entail above-average stock returns in the future. But it remains a risky bet, as no growth signals are in the green zone yet. While momentum is a popular investment factor, the value aspect might be the more important one, in the longer term. We recommend analyzing the stock with Obermatt’s Value, Safety, and Sentiment Ranks to arrive at a 360° View of the stock purchase case, especially since the growth performance is low here. ...read more

GROWTH METRICS	2022	2023	2024	2025
REVENUE GROWTH
REVENUE GROWTH	98	67	22	1
PROFIT GROWTH
PROFIT GROWTH	26	15	28	25
CAPITAL GROWTH
CAPITAL GROWTH	96	81	54	42
STOCK RETURNS
STOCK RETURNS	91	39	16	8
CONSOLIDATED RANK: GROWTH
CONSOLIDATED RANK: GROWTH	100	47	14	4

Last update of Growth Rank: 31-Jul-2025. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Chunghwa Chemical Synthesis & Biotech.

Safety Metrics in Detail

ANALYSIS: With an Obermatt Safety Rank of 37 (better than 37% compared with alternatives), the company Chunghwa Chemical Synthesis & Biotech has financing practices on the riskier side, which means that their overall debt burden is above the industry average. This doesn't mean that the business of Chunghwa Chemical Synthesis & Biotech is also risky, it only means that the company is on the riskier side in respect to bankruptcy in case things turn sour, assuming that public reporting is correct. The Safety Rank is based on consolidating three financing indicators, with just one indicator above average for Chunghwa Chemical Synthesis & Biotech and the other two below average. Refinancing is at 74, meaning the portion of the debt about to be refinanced is below average. It has less debt in the refinancing stage than 74% of its competitors. But Leverage is high with a rank of 35, meaning the company has an above-average debt-to-equity ratio. It has more debt than 65% of its competitors. Liquidity is also on the riskier side with a rank of 14, meaning the company generates less profit to service its debt than 86% of its competitors. ...read more

RECOMMENDATION: With a consolidated Safety Rank of 37 (worse than 63% compared with alternatives), Chunghwa Chemical Synthesis & Biotech has a financing structure that is riskier than that of its competitors. A good Refinancing Rank means that the problems of the company may not be around the corner. But high Leverage is only good if things go well, and low Liquidity is a signal for caution. The financing signals for Chunghwa Chemical Synthesis & Biotech are on the riskier side, requiring the company's future to be on the safer side. Investors may want to look at Growth and Sentiment ranks before making an investment decision. In the long-term, investors may have a debt challenge with Chunghwa Chemical Synthesis & Biotech and should also compare Obermatt’s Value, Growth, and Sentiment Ranks before making a decision. ...read more

SAFETY METRICS	2022	2023	2024	2025
LEVERAGE
LEVERAGE	94	47	33	35
REFINANCING
REFINANCING	27	57	63	74
LIQUIDITY
LIQUIDITY	61	61	31	14
CONSOLIDATED RANK: SAFETY
CONSOLIDATED RANK: SAFETY	72	61	38	37

Last update of Safety Rank: 31-Jul-2025. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Chunghwa Chemical Synthesis & Biotech and the more cash is available to service its debt.

Sentiment Metrics in Detail

SENTIMENT	2022	2023	2024	2025
ANALYST OPINIONS
ANALYST OPINIONS	n/a	20	20	^new
OPINIONS CHANGE
OPINIONS CHANGE	50	50	50	^new
PRO HOLDINGS
PRO HOLDINGS	98	30	52	^new
MARKET PULSE
MARKET PULSE	100	100	91	^new
CONSOLIDATED RANK: SENTIMENT
CONSOLIDATED RANK: SENTIMENT	100	41	70	^new

Last update of Sentiment Rank: 3-Apr-2025. Stock analysis on sentiment metrics: The higher the rank, the more positive the sentiment for Chunghwa Chemical Synthesis & Biotech.
Upgrade to a Premium Account to access the latest ranks.